Sugi Predict

Sugi Predict / Compounds / SCHEMBL1006653

SCHEMBL1006653

SCHEMBL1006653

c1cnc2c(c1)CCCO2

nearest known ligand 0.46

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ACHE P22303 5/20 0.46
▸ RIPK1 Q13546 1/20 0.40
▸ CTNNB1 P35222 1/20 0.38
▸ WNT3A P56704 1/20 0.38
▸ P2RX7 Q99572 3/20 0.37
▸ PDE1A P54750 4/20 0.37
▸ PDE1B Q01064 4/20 0.37
▸ PDE1C Q14123 4/20 0.37
▸ TSHR P16473 1/20 0.36
▸ SYK P43405 1/20 0.34
▸ GRM1 Q13255 1/20 0.33
▸ CHRNB2 P17787 1/20 0.33
▸ CHRNA7 P36544 1/20 0.33
▸ CHRNA4 P43681 1/20 0.33
▸ HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20897982 0.94 ACHE (0.42) ACHERIPK1CTNNB1WNT3AP2RX7
SCHEMBL618831 0.88 — —
SCHEMBL10200477 0.78 HTR2C (0.45) ACHEP2RX7CHRNB2CHRNA4HTR3A
Hydrochloric Acid SCHEMBL2112080 0.77 HTR2C (0.44) ACHEP2RX7CHRNB2CHRNA4HTR3A
SCHEMBL15713269 0.77 DRD2 (0.43) HTR3A
SCHEMBL30317484 0.77 PDE1A (0.41) ACHERIPK1PDE1APDE1BPDE1C
SCHEMBL20898034 0.73 CHRNB4 (0.41) ACHERIPK1CHRNB2CHRNA4
Benzamide SCHEMBL15129414 0.72 PARP1 (0.47) RIPK1P2RX7TSHR
SCHEMBL14776 0.72 ACHE (0.33) ACHECTNNB1WNT3AGRM1
SCHEMBL15269272 0.72 CHRNB2 (0.33) ACHEP2RX7CHRNB2CHRNA7CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11612606-B2 8-aminoisoquinoline compounds and uses thereof GENENTECH, INC. (US) 2023-03-28 — — US claimed
CN-112830933-A Synthetic method of 3, 4-dihydro-2H-pyrano [2,3-b ] pyridine 康化（上海）新药研发有限公司 2021-05-25 — — CN claimed
EP-2099800-A1 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION Pharmacopeia, LLC (US) 2009-09-16 — — EP claimed
US-20080287468-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2008-11-20 — — US claimed
US-20080119496-A1 7-Substituted Purine Derivatives for Immunosuppression PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-05-22 — — US claimed
WO-2008060301-A1 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA , LLC (US) 2008-05-22 — — WO claimed
EP-1874772-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2008-01-09 — — EP claimed
US-20070021443-A1 Purine and imidazopyridine derivatives for immunosuppression WYETH LLC 2007-01-25 — — US claimed
WO-2006108103-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION PHARMACOPEIA, INC. (US) 2006-10-12 — — WO claimed
EP-0519291-B1 Amino-methyl substituted 2,3-Dihydropyrano (2,3-b) pyridines, process for their preparation and their use in medicines BAYER AG (DE) 1997-01-08 — — EP claimed
US-5250540-A For treatment of disorders of the central nervous system BAYER AKTIENGESELLSCHAFT (DE) 1993-10-05 — — US claimed
EP-0519291-A1 Amino-methyl substituted 2,3-Dihydropyrano (2,3-b) pyridines, process for their preparation and their use in medicines BAYER AG (DE) 1992-12-23 — — EP claimed
EP-4711364-A1 FUSED PYRROLE RING OR FUSED PYRIDINE RING COMPOUND Pharmaengine, Inc. (TW) 2026-03-18 — — EP disclosed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 — — US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 — — EP disclosed
EP-4701737-A2 MTA-COOPERATIVE PRMT5 INHIBITOR Pharmaengine, Inc. (TW) 2026-03-04 — — EP disclosed
WO-1989001775-A1 AZOLIDINEDIONE DERIVATIVES PFIZER INC. (US) 1989-03-09 — — WO disclosed
WO-1989001775-A1 AZOLIDINEDIONE DERIVATIVES PFIZER INC. (US) 1989-03-09 — — WO disclosed
EP-0306251-A2 Azolidinedione derivatives PFIZER INC. (US) 1989-03-08 — — EP disclosed
EP-0306251-A2 Azolidinedione derivatives PFIZER INC. (US) 1989-03-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119496-A1 7-Substituted Purine Derivatives for Immunosuppression P2RX7, P2RX5, P2RY1 ACHE 3125/4885RIPK1 1327/4885CTNNB1 877/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH ACHE 102/4885RIPK1 3954/4885CTNNB1 2402/4885
US-20070021443-A1 Purine and imidazopyridine derivatives for immunosuppression TPMT, P2RY4, P2RY1 ACHE 3069/4885RIPK1 1459/4885CTNNB1 1408/4885
US-11612606-B2 8-aminoisoquinoline compounds and uses thereof PHKG1, MAP4K5, HIPK1 ACHE 4825/4885RIPK1 319/4885CTNNB1 4063/4885
US-20080287468-A1 PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION TPMT, P2RY4, P2RY1 ACHE 3069/4885RIPK1 1459/4885CTNNB1 1408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.